株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

胃食道 (GE) 接合部癌:パイプライン製品の分析

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 245990
出版日 ページ情報 英文 125 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
胃食道 (GE) 接合部癌:パイプライン製品の分析 Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2015
出版日: 2015年09月16日 ページ情報: 英文 125 Pages
概要

胃食道接合部癌は、食道や胃食道接合部 (GE) に生じる腺癌です。主な症状には、発語障害や体重減少、せき、嚥下痛、疼痛、しわがれ声などがあります。主な疾病素質として、加齢や体重超過・肥満症、胃食道逆流症 (GERD)、喫煙、飲酒などが挙げられます。主な治療法には、化学療法や放射線療法などがあります。

当レポートでは、世界各国での食道胃接合部癌治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要 (製品概要、機能メカニズム、研究開発 (R&D) の進展状況)、最新の業界動向などを調査しております。

イントロダクション

  • 分析範囲

胃食道接合部癌の概要

治療薬の開発

  • 胃食道接合部癌向けパイプライン製品:概要
  • 胃食道接合部癌向けパイプライン製品:比較分析

各企業で開発中の胃食道接合部癌治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

胃食道接合部癌治療薬:開発中の製品の一覧(企業別)

胃食道接合部癌治療薬の開発に従事している企業

  • Amgen Inc.
  • Aslan Pharmaceuticals Pte. Ltd.
  • AstraZeneca Plc
  • Basilea Pharmaceutica AG
  • Bristol-Myers Squibb Company
  • Celltrion, Inc.
  • Exelixis, Inc.
  • GlaxoSmithKline Plc
  • Hetero Drugs Limited
  • Merck & Co., Inc.
  • Merck KGaA
  • NantKwest, Inc.
  • 小野薬品工業
  • Sorrento Therapeutics, Inc.

胃食道接合部癌:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • アフレセルチブ塩酸塩
  • AMG-211
  • アベルマブ
  • BAL-101553
  • カボザンチニブ s-リンゴ酸塩
  • 腫瘍向けHER2標的の細胞療法
  • DKN-01
  • FS-102
  • ゲフィチニブ
  • haNKプログラム
  • イピリムマブ
  • MK-2206
  • ニモツズマブ
  • ニボルマブ
  • トラスツズマブのバイオシミラー
  • トラスツズマブのバイオシミラー
  • varlitinib

胃食道接合部癌治療薬:最新の薬剤プロファイル

胃食道接合部癌治療薬:開発が休止状態の製品

胃食道接合部癌治療薬:開発が中止された製品

胃食道接合部癌関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(1件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7111IDB

Summary

Global Markets Direct's, 'Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2015', provides an overview of the Gastroesophageal (GE) Junction Carcinomas's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gastroesophageal (GE) Junction Carcinomas
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gastroesophageal (GE) Junction Carcinomas and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gastroesophageal (GE) Junction Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gastroesophageal (GE) Junction Carcinomas pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastroesophageal (GE) Junction Carcinomas Overview
  • Therapeutics Development
    • Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Overview
    • Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis
  • Gastroesophageal (GE) Junction Carcinomas - Therapeutics under Development by Companies
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Gastroesophageal (GE) Junction Carcinomas - Products under Development by Companies
  • Gastroesophageal (GE) Junction Carcinomas - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Aslan Pharmaceuticals Pte. Ltd.
    • AstraZeneca Plc
    • Basilea Pharmaceutica AG
    • Bristol-Myers Squibb Company
    • Celltrion, Inc.
    • Exelixis, Inc.
    • GlaxoSmithKline Plc
    • Hetero Drugs Limited
    • Merck & Co., Inc.
    • Merck KGaA
    • NantKwest, Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Sorrento Therapeutics, Inc.
  • Gastroesophageal (GE) Junction Carcinomas - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • afuresertib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMG-211 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • avelumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAL-101553 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target HER2 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DKN-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FS-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gefitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • haNK Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ipilimumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MK-2206 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nimotuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • varlitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Gastroesophageal (GE) Junction Carcinomas - Recent Pipeline Updates
  • Gastroesophageal (GE) Junction Carcinomas - Dormant Projects
  • Gastroesophageal (GE) Junction Carcinomas - Discontinued Products
  • Gastroesophageal (GE) Junction Carcinomas - Product Development Milestones
    • Featured News & Press Releases
      • Feb 06, 2012: Aslan Pharma Receives KFDA And IRB Grants Approval To Initiate Phase IIa Study Of ASLAN001 At Seoul National University
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2015
  • Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Amgen Inc., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by AstraZeneca Plc, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Basilea Pharmaceutica AG, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Celltrion, Inc., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Exelixis, Inc., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Hetero Drugs Limited, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck & Co., Inc., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck KGaA, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by NantKwest, Inc., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Sorrento Therapeutics, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas Therapeutics - Recent Pipeline Updates, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Dormant Projects, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2015
  • Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top